imaging was observed in 68 patients, 7.4% of the patients with any axial imaging, 3.6% of the overall cohort. Patients with duplicate imaging differed significantly from the remainder of the cohort in clinicopathologic characteristics (higher PSA, p<0.001; higher cT stage, p¼0.015; higher Grade Group, p<0.001; higher NCCN risk category, p<0.001) but not demographic characteristics (age, race, family history of CaP, Charlson comorbidity score). 48% of providers were observed to utilize duplicate axial imaging, with significant variation by individual provider from 0% to 60%. A weak correlation was observed between individual provider 0 s patient volume and use of duplicate imaging (Spearman 0 s correlation 0.313, n¼56, p¼0.019).
MP08-17 IS MAGNETIC RESONANCE IMAGING SENSITIVE ENOUGH FOR PARTIAL GLAND HIGH INTENSITY FOCUSED ULTRASOUND TREATMENT? COMPARING PROSTATE CANCER LESIONS BETWEEN MAGNETIC RESONANCE IMAGING AND PROSTATECTOMY SPECIMENS
Clinton Bahler*, Clint Cary, Ronald Boris, Temel Tirkes, Timothy Masterson, Thomas Gardner, Michael Koch, Indianapolis, IN INTRODUCTION AND OBJECTIVES: Focal ablation during high intensity Focused ultrasound (HIFU) offers reduced comorbidities, but increased risk of untreated disease. Magnetic resonance imaging (MRI) is increasingly being used to select patients for focal HIFU. Our objective was to characterize how well MRI fusion biopsy identifies disease within the prostate by studying men who have underwent a MRI fusion biopsy and subsequent radical prostatectomy.
METHODS: A prospective database was queried for a history of radical prostatectomy and MRI fusion biopsy. Men underwent a 3 Tesla multi-parametric MRI, one of two radiologists evaluated all MRI scans, and lesions were scored from 1-5 using an institution specific system. A genitourinary pathologist reviewed all prostatectomy specimens and primary and secondary lesions were reported. Differences between MRI lesions and prostatectomy tumor foci were assessed for size, Gleason score, and laterality. Means were compared using students t-test and all statistical analysis was performed using Stata 13.1. RESULTS: Fifty-eight patients underwent MRI-fusion and 12-core biopsy followed by prostatectomy with a total of 702 biopsy cores evaluated. The median (IQR) age ¼ 66.4years (60-70), PSA ¼ 9.3ng/mL (6-15), and number of prior biopsies ¼ 1 (0-2). Final Gleason score was as follows: 6¼ 2(3%), 7¼ 46(79%), and 8-9¼ 10(17%). There were a total of 120 MRI lesions with a median (range) of 2 (1-5) marked for fusion biopsy per patient, and a mean of 2.4 fusion biopsies per lesion. A MRI lesion was found in the quadrant of the primary (largest) surgical pathologic focus in 45/58 (78%). However, of these MRI lesions only 24 (53%) had matching grade with 12 benign biopsies being upgraded to Gleason 7 on surgical pathology. The mean MRI lesion greatest dimension was 1.9cm compared to 2.2cm on final pathology (p¼0.03). MRI lesions were similar in size to final pathology (not more than 1cm smaller) in 37/45 (82%) while 3 (7%) were 1-1.9cm smaller and 5 (11%) were 2cm smaller. A total of 23/58 (40%) had fusion biopsy Gleason 7 on a single side, and on final pathology 14 (61%) had a secondary focus of bilateral disease.
CONCLUSIONS: A significant number of surgical specimens contained lesions larger than predicted by MRI or had bilateral disease when only unilateral disease was seen on biopsy. When considering focal HIFU, it would be prudent to treat a larger area surrounding the dominant MRI lesion. Furthermore, follow-up biopsies of the contralateral untreated lobe are imperative. METHODS: PubMed, Embase and the Cochrane Library were searched for relevant studies with a publication date through March 2016. The methodological quality was assessed using QUADAS tools. Data synthesis was calculated using Meta-Disc Version 1.4. RESULTS: Of the 137 studies identified, 11 were included with 1407 patients. Methodological assessment demonstrated study quality was moderate to high. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve of SWE for detecting malignant prostatic nodules were 85 % (95% CI, 82-87%), 84 % (95% CI, 82-86%), and 92% (95% CI, 90-95%), respectively. Positive and negative predictive values were 27.7-44.7% and 98.1-99.1 %. The positive and negative likelihood ratio were 4.45 (95% CI: 2.87-6.89) and 0.18 (95% CI: 0.11-0.32). The summary diagnostic OR was 28.48 (95% CI: 12.42-65.35). Publication bias regression test revealed no significant small-study bias.
CONCLUSIONS: Shear wave elastography is a highly accurate diagnostic method for the identification of prostate cancer using the histopathology as the reference standard and may help to reduce the number of core biopsies in the future.
INTRODUCTION AND OBJECTIVES: Pelvic MRI can be used in the setting of prostate cancer for pre-surgical evaluation of local disease extension although limitations are debated. Less often discussed, however, is the human component; specifically, the radiologist interpreting the study. Herein, we investigate the accuracy and variability of pelvic MRI interpretation among our body radiology team versus a senior faculty member.
METHODS: A single institution retrospective study identified 233 consecutive individuals diagnosed with prostate cancer who ultimately had a prostatectomy. All patients had pre-surgical pelvic 3T surface body coil MRI read by a fellowship trained body radiologist provided with relevant clinical information. Thereafter, a senior radiologist was selected to re-read all pelvic MRIs blinded to the initial interpretation. Both MRI readings were compared to final pathology report. Kappa (K) scores as well as sensitivity, specificity, positive predictive values (PPV), negative predictive value (NPV), and accuracy were calculated.
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